α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients

European Respiratory Journal

Volumn 29, Issue 2, 2007, Pages 240-250

  Griese, Matthias ^a   Latzin, P ^a   Kappler, M ^a   Weckerle, K ^a   Heinzimaier, T ^a   Bernhardt, T ^b   Hartl, D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Bayer Healthcare Biological Products ^*  (Germany)

Author keywords

1 Antitypsin; Cystic fibrosis; Elastase; Interleukin 8; Neutrophils

Indexed keywords

ALPHA 1 ANTITRYPSIN; CYTOKINE; ELASTASE; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOTRIENE B4; TUMOR NECROSIS FACTOR ALPHA; PANCREATIC ELASTASE; SERINE PROTEINASE INHIBITOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL PAIN; HEMOPTYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEBULIZER; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; ADOLESCENT; BLOOD; BRONCHUS; CHEMISTRY; CHILD; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMONIA; SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALPHA 1-ANTITRYPSIN; BRONCHI; CHILD; CYSTIC FIBROSIS; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PANCREATIC ELASTASE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; SERINE PROTEINASE INHIBITORS; SPUTUM; TREATMENT OUTCOME;

EID: 33846907545     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00047306     Document Type: Article

References (37)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-1256.
2. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24: 137-142.
3. Döring G, Goldstein W, Botzenhart K, et al. Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol 1986; 64: 597-605.
4. Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991; 4: 26-32.
5. Kimbel P. Proteolytic lung damage. Chest 1980; 77: 274-276.
6. Suter S, Schaad UB, Morgenthaler JJ, Chevallier I, Schnebli HP. Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis. J Infect Dis 1988; 158: 89-100.
7. Griese M, Wiesener A, Lottspeich F, von Bredow C. Limited proteolysis of surfactant protein D causes a loss of its calcium-dependent lectin functions. Biochim Biophys Acta 2003; 1638: 157-163.
8. von Bredow C, Wiesener A, Griese M. Proteolysis of surfactant protein D by cystic fibrosis relevant proteases. Lung 2003; 181: 79-88.
9. Fick RB Jr, Baltimore RS, Squier SU, Reynolds HY. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis 1985; 151: 589-598.
10. Berger M, Dearborn D, Legris G, Döring G, Sorensen R. Complement receptor expression on neutrophils (PMN) in the lung in cystic-fibrosis (CF). Pediatr Res 1986; 20: A305.
11. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G. Complement receptor expression on neutrophils at an inflammatory site, the pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989; 84: 1302-1313.
12. Döring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 1995; 154: 4842-4850.
13. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478-1484.
14. 4 by alveolar macrophages. J Clin Invest 1991; 88: 891-897.
15. Birrer P. Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies. Respiration 1995; 62: Suppl. 1, 25S-28S.
16. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
17. Suter S, Chevallier I. Proteolytic inactivation of alpha 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis. Eur Respir J 1991; 4: 40-49.
18. Allen ED. Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis. Chest 1996; 110: Suppl. 6, 256S-260S.
19. Brand P, Meyer T, Haussermann S, et al. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 2005; 18: 45-54.
20. Hilliard J, Konstan MW, Davis PB. Inflammatory mediators in CF patients. Methods Mol Med 2002; 70: 409-431.
21. Hogardt M, Trebesius K, Geiger AM, Hornef M, Rosenecker J, Heesemann J. Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients. J Clin Microbiol 2000; 38: 818-825.
22. Alexis N, Soukup J, Ghio A, Becker S. Sputum phagocytes from healthy individuals are functional and activated: a flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood. Clinical Immunology 2000; 97: 21-32.
23. Fick RB Jr, Naegel GP, Squier SU, Wood RE, Gee JB, Reynolds HY. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest 1984; 74: 236-248.
24. Döring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: 114-117.
25. Bainbridge T, Fick RB Jr. Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase. J Lab Clin Med 1989; 114: 728-733.
26. Kolb G, Eckle I, Heidtmann HH, Neurath F, Havemann K. Neoantigenic group on Fc fragments in rheumatoid arthritis synovial fluids. Scand J Rheumatol Suppl 1988; 75: 179-189.
27. Eckle I, Kolb G, Havemann K. Inhibition of neutrophil oxidative burst by elastase-generated IgG fragments. Biol Chem Hoppe Seyler 1990; 371: 69-77.
28. Eckle I, Kolb G, Havemann K. Inhibition of neutrophil chemotaxis by elastase-generated IgG fragments. Scand J Immunol 1991; 34: 359-364.
29. Eckle I, Kolb G, Havemann K. Regulation of neutrophil functions by elastase-generated IgG fragments. Arch Immunol Ther Exp (Warsz) 1992; 40: 43-47.
30. Brand P, Beckmann H, Maas EM, et al. Peripheral deposition of alphal-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22: 263-267.
31. Nita I, Hollander C, Westin U, Janciauskiene SM. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res 2005; 6: 12.
32. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72-78.
33. Cantin A, Woods DE. Aerolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med 1999; 160:1130-1135.
34. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
35. Ratjen F, Rietschel E, Griese M, et al. Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Bronchoalveolar lavage for the evaluation of anti-inflammatory treatment (BEAT) study group. Eur Respir J 2000; 15: 141-145.
36. Reinhardt N, Chen CI, Loppow D, et al. Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL. Eur Respir J 2003; 22: 497-502.
37. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006; 41: 177-183.